<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33474827</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-7714</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Thoracic cancer</Title><ISOAbbreviation>Thorac Cancer</ISOAbbreviation></Journal><ArticleTitle>Tumor-educated platelet SNORD55 as a potential biomarker for the early diagnosis of non-small cell lung cancer.</ArticleTitle><Pagination><StartPage>659</StartPage><EndPage>666</EndPage><MedlinePgn>659-666</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1759-7714.13823</ELocationID><Abstract><AbstractText Label="BACKGROUND">Despite the emerging insights into many snoRNAs (small nucleolar RNAs) which are detectable in body fluids and serve as noninvasive biomarkers, few studies have previously discussed the role of snoRNAs in tumor-educated platelets (TEPs). Herein, we systematically estimated dysregulation of snoRNAs in non-small cell lung cancer (NSCLC) and clarified the biomarker potential of SNORD55 in platelets.</AbstractText><AbstractText Label="METHODS">We compared expression of snoRNAs between NSCLC and normal tissues using SNORic datasets. Platelets were isolated from plasma using low-speed centrifugation and subjected to quantitative polymerase chain reaction (qPCR) for SNORD55 detection.</AbstractText><AbstractText Label="RESULTS">SNORD55 was significantly decreased in TEPs from NSCLC patients especially in early-stage patients compared with healthy controls. Importantly, we validated that TEP SNORD55 was capable of acting as a promising biomarker for NSCLC. It exerted diagnostic performance for NSCLC diagnosis, possessing an AUC of 0.803, as well as for early NSCLC diagnosis, possessing an AUC of 0.784. Moreover, the combination of TEP SNORD55 and carcinoembryonic antigen (CEA) improved the diagnostic efficiency of cancer progression. In addition, TEP SNORD55 also potentially acts as a noninvasive early biomarker for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) with favorable diagnostic efficiencies.</AbstractText><AbstractText Label="CONCLUSIONS">In summary, TEP SNORD55 could potentially serve as a noninvasive biomarker for NSCLC diagnosis and early diagnosis.</AbstractText><AbstractText Label="KEY POINTS">SNORD55 was significantly decreased in TEPs from NSCLC patients compared to healthy controls and acted as a novel biomarker for early NSCLC.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Xiaohan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Graduate, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xingguo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kangyu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Graduate, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Graduate, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4715-136X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xianrang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-1722-8207</Identifier><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81972014</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81672104</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>ZR2019LZL016</GrantID><Agency>Shandong Provincial Natural Science Foundation</Agency><Country/></Grant><Grant><GrantID>ZR2019MH004</GrantID><Agency>Shandong Provincial Natural Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Thorac Cancer</MedlineTA><NlmUniqueID>101531441</NlmUniqueID><ISSNLinking>1759-7706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SNORD55</Keyword><Keyword MajorTopicYN="N">TEP</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">snoRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>21</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33474827</ArticleId><ArticleId IdType="pmc">PMC7919130</ArticleId><ArticleId IdType="doi">10.1111/1759-7714.13823</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adjei AA. Lung cancer worldwide. J Thorac Oncol. 2019;14(6):956.</Citation><ArticleIdList><ArticleId IdType="pubmed">31122558</ArticleId></ArticleIdList></Reference><Reference><Citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Cancer statistics 2006. CA Cancer J Clin. 2006;56(2):106&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16514137</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalobos P, Wistuba II. Lung cancer biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5137804</ArticleId><ArticleId IdType="pubmed">27912828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefrancais E, Ortiz&#x2010;Mu&#xf1;oz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663284</ArticleId><ArticleId IdType="pubmed">28329764</ArticleId></ArticleIdList></Reference><Reference><Citation>Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010;328(5978):562&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20430990</ArticleId></ArticleIdList></Reference><Reference><Citation>Best MG, Wesseling P, Wurdinger T. Tumor&#x2010;educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res. 2018;78(13):3407&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">29921699</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson RJ, Balaj L, Hulleman E, Van Rijn S, Pegtel DM, Walraven M, et al. Blood platelets contain tumor&#x2010;derived RNA biomarkers. Blood. 2011;118(13):3680&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224637</ArticleId><ArticleId IdType="pubmed">21832279</ArticleId></ArticleIdList></Reference><Reference><Citation>Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA&#x2010;Seq of tumor&#x2010;educated platelets enables blood&#x2010;based pan&#x2010;cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28(5):666&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644263</ArticleId><ArticleId IdType="pubmed">26525104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafontaine DL, Tollervey D. Birth of the snoRNPs: the evolution of the modification&#x2010;guide snoRNAs. Trends Biochem Sci. 1998;23(10):383&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9810226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaille J, Nicoloso M, Bachellerie JP. Targeted ribose methylation of RNA in vivo directed by tailored antisense RNA guides. Nature. 1996;383(6602):732&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganot P, Bortolin ML, Kiss T. Site&#x2010;specific pseudouridine formation in preribosomal RNA is guided by small nucleolar RNAs. Cell. 1997;89(5):799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">9182768</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipowicz W, Pogacic V. Biogenesis of small nucleolar ribonucleoproteins. Curr Opin Cell Biol. 2002;14(3):319&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12067654</ArticleId></ArticleIdList></Reference><Reference><Citation>Falaleeva M, Pages A, Matuszek Z, Hidmi S, Agranat&#x2010;Tamir L, Korotkov K, et al. Dual function of C/D box small nucleolar RNAs in rRNA modification and alternative pre&#x2010;mRNA splicing. Proc Natl Acad Sci U S A. 2016;113(12):E1625&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812717</ArticleId><ArticleId IdType="pubmed">26957605</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishore S, Khanna A, Zhang Z, Hui J, Balwierz PJ, Stefan M, et al. The snoRNA MBII&#x2010;52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum Mol Genet. 2010;19(7):1153&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838533</ArticleId><ArticleId IdType="pubmed">20053671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray PF, McKenzie SE, Edelstein LC, Nagalla S, Delgrosso K, Ertel A, et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics. 2013;14:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722126</ArticleId><ArticleId IdType="pubmed">23323973</ArticleId></ArticleIdList></Reference><Reference><Citation>Best MG, Vancura A, Wurdinger T. Platelet RNA as a circulating biomarker trove for cancer diagnostics. J Thromb Haemost. 2017;15(7):1295&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">28671345</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastings ML, Krainer AR. Pre&#x2010;mRNA splicing in the new millennium. Curr Opin Cell Biol. 2001;13(3):302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343900</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X, Ding S, Yu M, Niu L, Xue L, Zhao Y, et al. Small nuclear RNAs (U1, U2, U5) in tumor&#x2010;educated platelets are downregulated and act as promising biomarkers in lung cancer. Front Oncol. 2020;10:1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434840</ArticleId><ArticleId IdType="pubmed">32903345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehr S, Bartschat S, Tafer H, Stadler PF, Hertel J. Matching of Soulmates: coevolution of snoRNAs and their targets. Mol Biol Evol. 2014;31(2):455&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">24162733</ArticleId></ArticleIdList></Reference><Reference><Citation>Best MG, Sol N, In't Veld SGJG, Vancura A, Muller M, ALN N, et al. Swarm intelligence&#x2010;enhanced detection of non&#x2010;small&#x2010;cell lung cancer using tumor&#x2010;educated platelets. Cancer Cell. 2017;32(2):238&#x2013;252 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6381325</ArticleId><ArticleId IdType="pubmed">28810146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HH, Lee JJ, Chen HM, Kok SH, Kuo MY, Cheng SJ, et al. Upregulation of vascular endothelial growth factor mRNA level is significantly related to progression and prognosis of oral squamous cell carcinomas. J Formos Med Assoc. 2015;114(7):605&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">26058869</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9(9):1826&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8880098</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21&#x2010;1, SCC and NSE) in patients with non&#x2010;small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24(4):209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv S, Xue J, Wu C, Wang L, Wu J, Xu S, et al. Identification of a panel of serum microRNAs as biomarkers for early detection of lung adenocarcinoma. J Cancer. 2017;8(1):48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5264039</ArticleId><ArticleId IdType="pubmed">28123597</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29313949</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">26667336</ArticleId></ArticleIdList></Reference><Reference><Citation>Egidi MG, Cochetti G, Guelfi G, Zampini D, Diverio S, Poli G, et al. Stability assessment of candidate reference genes in urine sediment of prostate cancer patients for miRNA applications. Dis Markers. 2015;2015:973597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4452852</ArticleId><ArticleId IdType="pubmed">26078486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>